Study Evaluating MST-997 in Advanced Malignant Solid Tumors
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
MST-997 is a taxane analog with the potential to treat subjects with a variety of tumor
types. Preclinical data demonstrated that MST-997 inhibited tumor growth when administered
intravenously (IV). This phase 1 dose escalation study is designed to evaluate the safety and
tolerability of if IV MST-997 formulated in Polysorbate 80 Diluent can be safely administered
on a weekly basis.